Sterimed Holding SAS

Based in France, STERIMED Infection Control specializes in developing sterilization packaging solutions for the medical and pharmaceutical sectors, ensuring device safety and infection control within healthcare environments. STERIMED Infection Control is a manufacturer that focuses on sterilization packaging solutions for the healthcare industry. Founded in 1911, the company is headquartered in Boulogne Billancourt, France. The CEO is Sophie MANIGLIER.

In April 2025, a consortium led by the company's management, including RAISE, CAPZA, GENEO Capital Entrepreneur, Société Générale Capital Partenaires, Sagard, IK Partners and along with undisclosed investors, agreed to acquire, STERIMED Infection Control. As part of the deal, Sagard reinvested in the business. Sterimed is a leading manufacturer specializing in the production of sterilization packaging solutions tailored for the medical device, hospital, and pharmaceutical sectors. Their core product offerings include a range of sterilizable materials designed for the creation of hospital pouches, reels, and wraps.

These products are engineered to ensure that medical devices are properly sterilized and maintained in a sterile state until their application on patients, thereby significantly contributing to infection prevention. Sterimed's packaging solutions cater to a diverse clientele, including medical device manufacturers, hospitals, and pharmaceutical companies across multiple geographical markets, including Europe, Asia, and the Middle East. The company’s commitment to innovation and quality has positioned it as a trusted partner in the healthcare industry, enhancing patient safety and operational efficiency for its customers. Sterimed generates revenue through direct business transactions primarily with B2B clients within the healthcare sector.

The structure of these transactions typically involves the sale of specialized sterilization packaging products, which are provided on a contractual basis. Clients engage in long-term partnerships to procure Sterimed's flagship products, such as ETHYPEL®, POLYBOND®, and ETHYFORM®, which are integral to their operational needs. The pricing structure is determined based on the specific requirements of each client, reflecting the customized nature of the products and services offered. Due to the specificity and regulatory aspects of the medical packaging industry, transactions are often tailored to meet the unique needs and compliance standards of each client, ensuring that Sterimed remains a competitive and reliable supplier in the market.